The first treatment for rare lung disease was approved; 5.6 billion sales, the ace of stone medicine welcomed the first opponent; Howson took the first imitation; BI, Takeda, Zhengda, green leaves...

Read: The Latest! A week of drug trials, it's all heavy-duty drugs..This week's look:take stock of this week's high-profile drug information5.6 billion market, the first new drug for the improvement of butyl benzene injection seision was reported to the marketTakeda rapid layout of the Chinese market, within six months 2 applications for new indicationsHowson was approved for the first copy and forced againthis issue (May 29-June 5), drug news is emerging, from international to domestic, from first-line drugs to rare disease drugs, from new drugs to genericdrugs and so on, there is good news, the following inventory of some of the heavy drugs..International lying drug informationthe first-line field of liver cancer has welcomed the first immunotherapy program
this issue of international attention is Roche's gene TekPD-L1 inhibitor Tecentriq (atezolizumab) in conjunction with the anti-angiogenic drug Avastin ("Bevacizumab"), the first-line treatment can not be removed or metastatic liver cell cancer patientsIn addition, with the end of ASCO, liver cancer, a major cancer species finally ushered in a major outbreak, about the 2020 liver cancer market, details click: a new era of liver cancer! Who are the companies entering?Fuhong's Qutozhu Monostavirus was approved by the EUROPEAN Union CHMP for the"Chinese nationality" HLX02 "Qutozhuzumab" EU listing application approved by EMA CHMP for the treatment of HER2-positive early-stage breast cancer, HER2-positive metastatic breast cancer, as well as untreated HER2-positive metastatic gastric cancer or gastric/esophagus adenocarcinoma patientsthis issue of domestic listed key drugsBaiji Shenzhou's Zebutini listedBaiji Shenzhou BTK inhibitor Zebutini capsules (Bai Yueze) approved by the State Drug Administration conditional listing, is the first To china CSCO guidelines and the United States National Comprehensive Cancer Network guidelines recommended by the two local research and development of new anti-cancer drugs, MCL/CLL/SLL adaptation,the world's first and only MPS I enzyme replacement therapy approved in China
the National Drug Administration approved Genzyme's injection-based Laroninase-thick solution (Aiezan) for the market for long-term enzyme replacement therapy for patients with mucosal polysaccharide i (MPS I) for the treatment of non-nervous system performance of the disease through a priority review and approval process As an enzyme replacement therapy for MPS I patients, it has been included in the second batch of clinically urgently needed overseas listed drugs Search Drug Intelligence News To see "The world's first and only MPS I enzyme replacement therapy, injected with laronine concentrative solution approved in China" () BI's Nidanib approved for the second indications Nidanib is a small molecular cheese developed by Bollinger Ingehan (BI) TKI, a domestic approval for the treatment of isoplasmfibrofibrosis (IPF) in September 2017, and the product name Vigat, this time harvested a second indication in China: systemic sclerosis-related interstitial pulmonary disease (SSc-ILD) At present, there are no drugs approved in China for interstitial pulmonary disease associated with systemic sclerosis Green Leaf Pharmaceuticals' clear-and-transdermal paste in China the first batch of Liss's bright paste is developed by The Peel Group's German subsidiary Luye Pharma AG's transdermal paste research and development platform for the treatment of Alzheimer's disease, is one of the core products of Green Leaf Pharmaceuticals in the central nerve field, the product and its formulation process is protected by a number of patents worldwide Currently, it has been approved for sale in more than 20 countries around the world Domestic similar products only Novartis Ace can be approved for sale Haussen's first imitation of Malayic acid Afatini tablets Afatinib (Gilotri), by BI Original Research, is the world's first irreversible EGFR lung cancer target drug, in February 2017 was approved for domestic market, this Time Howson Pharmaceuticals according to the new 4 categories of declared Malay acid afatinib tablets approved, as the same through consistency evaluation, the first generic drug in China The drug is currently a number of domestic layout, Qilu, Kolun, Zhengda Qing, Yangzijiang, Stone Medicine, Jiangxi Xiangshan has submitted the listing application However, the patent for the Afatini compound expires in 2021 after Haussen Afatini was unable to go on the market the new acceptance of the domestic review and approval this week CDE added 28 (21 varieties), 2 new drugs, the first new drug for the improvement of butyl benzene injection and the recombinant human coagulation factor VIII Dayqing; In 1978, the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences was first separated from the water celery seeds, the first chemically synthetic butyl benzene was obtained in 1980, in 1999 the stone drug was patented with 50 million, and in 2005 the stone drug group butyl benzene softgel (commodity name: Enbipu) was officially listed, becoming an innovative drug with china's own intellectual property rights after artemisinin and bicyclic ring In April 2010, a new dosage form of sodium butylbenzene chloride was approved for production, and in 2017, the dosage form was successfully included in the national health insurance catalog the product is the main fist products of Stone Pharmaceutical Group, sales in 2019 reached 5.6 billion yuan, in the field of neurology, has a broad market demand and market recognition At present, the domestic Nanjing Youke and Lizhu layout of the product, Youke to 2.2 class of declaration of butyl benzene injection has been accepted, it is understood that its preparation has obvious clinical advantages, if approved, will be with the stone medicine to grab the market data source: drug registration and acceptance database
in the research and development and production of butyl benzene products, stone drugs occupy the absolute market position, first of all, stone medicine has been on the all-round layout of butyl benzene products, butyl benzene tablets, l-butyl benzene tablets, l-butyl benzene injections and other innovative drugs are systematically declared Secondly, stone medicine applied for a patent for the preparation of new indications of butyl phenylene, le-butyl benzodiazepine, and butyl benzodiazepine-related substances The full layout, new indications and the development of new markets will all open up new growth opportunities for the stone drug butyl benzene market Recently, Embiid's Phase III clinic for the treatment of vascular dementia has been officially approved by the GeneticS Office Therefore, in the face of strong stone medicine, Nanjing Youke another way or face up to? Takeda's new acid inhibitor- Takeda Fuma acid Vonola tablets, on December 18, 2019, was approved in China for the treatment of reflux esophagitis, is the first potassium ion competitive acid blocker (P-CAB) approved to enter the Chinese market So far, Walker domestic approval less than half a year, during the period, two consecutive submissions of new indications listing applications, a series of actions enough to show its importance to the Chinese market in addition, pharmaceutical data query, Takeda Fuma acid Vonola tablets in China a total of 5 clinical trials, of which 3 Phase III clinical trials have been completed, and zhengda Tianqing, Shandong New Era Pharmaceuticals, Hangzhou East China Pharmaceuticals and Shandong Futron Pharmaceutical layout of its generic drugs Zhengda Dayqing - Recombinant Human Coagulation Factor VIII Zhengda Qing injection recombinant human coagulation factor VIII Is the second domestic manufacturer to submit the listing application for this variety after Shenzhou cells According to statistics, the domestic has been approved for listing of blood-borne coagulation factor VIII manufacturers have Shanghai Laishi, Hualan Biological and Chengdu Shengsheng Pharmaceuticals and other 7, recombinant human coagulation factor VIII due to the production process technology threshold is high, production difficulty, has not yet been approved for listing of domestic recombinant human coagulation factor protein drugs At present, it is mainly dependent on imports, with Bayer, Pfizer and Baxter Hausen-Nzaluamine softgels, injectable carfyzomi enzalutamide, an androgen receptor signaling inhibitor originally developed by Astellas/Pfizer, is the first oral treatment approved by the U.S FDA to treat three different forms of advanced prostate cancer, with sales of more than $4 billion in 2019 With domestic approval in November 2019, Howson is the first company in the country to submit an application for a generic nzarumine In addition, Colleen Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Shanxi Zhendong Pharmaceuticals and other enterprises have also submitted nzarumine clinical trial applications carfilzomib, Kyprolis, a proteosome inhibitor originally developed into the company, was first approved by the FDA for listing in July 2012 According to the data query, there is no kafizomi preparation approved for listing in China, of which Amjin has submitted a listing application in China in November 2019, is currently in the process of review and approval data sources: drug intelligence data, enterprise announcements and other network public data
information sources: drug intelligence network, enterprise announcements and other network public information